BATF3 and neoplasm: As expected, upon femoral inoculation of Batf3+/+ or Batf3−/− mice with LLC cells, only tumor-bearing Batf3+/+ mice but not Batf3−/− mice exhibited a decrease in local tumor burden at d17 following DMXAA treatment (Fig. 6i).